HomeKYNB • NASDAQ
add
Kyntra Bio Inc
Nakaraang pagsara
$7.19
Sakop ng araw
$7.20 - $7.39
Sakop ng taon
$6.32 - $9.70
Market cap
29.62M USD
Average na Volume
28.13K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.28M | -59.27% |
Gastos sa pagpapatakbo | 7.25M | -13.13% |
Net na kita | -14.22M | -179.08% |
Net profit margin | -1.11K | -294.14% |
Kita sa bawat share | -3.51 | -75.50% |
EBITDA | -13.51M | 49.92% |
Aktuwal na % ng binabayarang buwis | 0.00% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 88.98M | 76.26% |
Kabuuang asset | 119.59M | -44.25% |
Kabuuang sagutin | 115.12M | -71.09% |
Kabuuang equity | 4.48M | — |
Natitirang share | 4.05M | — |
Presyo para makapag-book | -0.97 | — |
Return on assets | -26.34% | — |
Return on capital | -110.83% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -14.22M | -179.08% |
Cash mula sa mga operasyon | -18.33M | 39.84% |
Cash mula sa pag-invest | -51.71M | -3,101.28% |
Cash mula sa financing | -14.00K | -380.00% |
Net change in cash | -70.10M | -143.20% |
Malayang cash flow | -10.14M | 90.52% |
Tungkol
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Itinatag
Ene 1, 1993
Headquarters
Website
Mga Empleyado
34
